Done With SCH772984 ? Then Look At This!

The use of current anti-angiogenic therapies is limited by many side-effects. In clinical trials with sunitinib, sorafenib and anti-VEGF antibody bevacizumab, a range of side-effects were observed in patients such as diarrhoea, hypertension, nausea, skin toxicities and mild thrombotic and bleeding events [73, http://www.selleckchem.com/products/sch772984.html 74]. The ideal treatment of CLDs has not been found yet, however, progress has been made over the years and future studies may support this progress. The authors wish to thank the Fund for Scientific Research (FWO Flanders) for the material support (3G075112) and Ghent University for the financial support. Hans Van Vlierberghe is Senior Researcher of the FWO. Financial support: Ghent University. Conflict of interest: The authors do not have any disclosures to report. ""Salvage liver transplantation (SLT) is an attractive sequential strategy which combines liver resection (LR) for hepatocellular carcinoma (HCC), followed by liver transplant (LT) in the event of HCC recurrence or progressive liver deterioration. To compare the long-term results of SLT with primary liver transplant (PLT). Between 2000 and 2011, 125 patients (72 transplantable) underwent LR and 226 underwent LT in our unit. The outcome of SLT was analysed in a two-step fashion: firstly, SLT (n?=?28) was compared with PLT (n?=?198), secondly an intention-to-treat analysis was performed on all transplantable HCC patients who underwent LR (LRT group?=?72) compared to PLT (n?=?198). The five-year overall survival (OS) was 65.4% vs. 49.2% http://www.selleck.cn/products/z-vad-fmk.html (P?=?0.63), and disease-free survival (DFS) was 89.7% vs. 80.6% (P?=?0.31) http://www.selleckchem.com/products/dabrafenib-gsk2118436.html for PLT and SLT respectively. Predictive factors for DFS after LT included HCC total diameter [hazard ratio (HR) 1.29 P?=?0.003], alpha-foetoprotein (HR 1.002 P?